Prospective study on adaptive as well as the stereotactic high precision radiotherapy in patients in palliative care

Prospective study on adaptive as well as the stereotactic high precision radiotherapy in patients in palliative care - AI LIFECARE

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00038665

Enrollment

500

Registered

2026-03-06

Start date

2026-03-07

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palliative care and radiotherapy, symptom relief, local therapy, high-precision therapy, efficiency, safety

Interventions

Group 1: Adaptive radiotherapy (combination of IGRT/IMRT/VMAT and ART/SGRT and/ or SBRT/SRS): the fractions of an RT series are evaluated and compared onboard with the standard option (plan comparison

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: palliative treatment

Exclusion criteria

Exclusion criteria: therapy denial

Design outcomes

Primary

Measure	Time frame
Dose distribution and effective uniform dose in the CTV over the first 7 fractions =95%, or <95%. (As a primary endpoint, the accumulated dose distribution in the CTV with the initial treatment plan approved for the series over fractions 1-7 of each patient is determined up to the time of the 10th fraction for each patient in this study, and from this the effective uniform dose in the CTV is calculated)	—

Measure

Time frame

Dose distribution and effective uniform dose in the CTV over the first 7 fractions =95%, or <95%. (As a primary endpoint, the accumulated dose distribution in the CTV with the initial treatment plan approved for the series over fractions 1-7 of each patient is determined up to the time of the 10th fraction for each patient in this study, and from this the effective uniform dose in the CTV is calculated)

—

Secondary

Measure	Time frame
minimal isotropic PTV margin, Progression-Free Survival (PFS), Overall Survival (OS), dose to organs at risk (OAR), side effects (CTC AE, LENT-SOMA); quality of life (EORTC), minimal isotropic PTV margin, dose coverage of the CTV with an equivalent uniform dose (EUD) of =95% of the prescribed dose	—

Countries

Germany

Contacts

Public ContactMaja Guberina

Universitätsklinikum Essen

maja.guberina@uk-essen.de00492017232322

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026